Marcel Trefny

Scientist working on Cellular Cancer Immunotherapies @LMU_Uniklinikum.

Previously working with @AlfredZippelius @DepBiomedicine

[Marcel Trefny @MarcelTrefny]

So excited to see our research published in @NatureComms today 🤩 https://t.co/6K1RWtmA8M
Tweetorial below🧵Thanks to all the great people involved, including on Twitter: @AlfredZippelius @NKirchhammer @priska_adm @natoli_marina @LImmunotherapy @HessLab @maryam_akrami 1/10

[Marcel Trefny @MarcelTrefny]

Very excited to share our review on "Metabolites as agents and targets for cancer immunotherapy" in @NatRevDrugDisc! read it here: https://t.co/zYlOay0tdP
@SpringerNature @KlinPharm

[Marcel Trefny @MarcelTrefny]

Happy to present our 'Expert Opinion' on "CAR T cells for solid tumors – developments to watch in 2023" https://t.co/EQXMlcLPrh
@KlinPharm

[Marcel Trefny @MarcelTrefny]

Congratulations Simon!

[Simon L. April-Monn, PhD @SimonAprilMonn]

🚨𝐏𝐚𝐩𝐞𝐫𝐀𝐥𝐞𝐫𝐭🚨FreshOfPress 𝑶𝒖𝒓 #𝑵𝑬𝑻𝑮3𝑵𝑬𝑪 #𝒕𝒖𝒎𝒐�#𝒕𝒖𝒎𝒐𝒓𝒐𝒊𝒅 𝒔𝒄𝒓𝒆𝒆𝒏 @Nature_NPJ #LetsTalkAboutNETs #cancer #organoid ex vivo @CureNETs @Soc_Endo 𝐊𝐮𝐝𝐨𝐬 2col @unibern @ChariteBerlin @ng_tma @Bernomics @Swiss3RCC @MedFacultyUniBE
https://t.co/SONyjXUnGp

[LMU Clinical Pharmacology @KlinPharm]

Huge congratulations to Prof. Sebastian Kobold for receiving an @ERC_Research consolidator grant for his project: CATACLIS - Cancer tailored next generation cellular therapies💐@LMU_Muenchen #ERC

[Cancer Research @CR_AACR]

#OnlineFirst: Read the In the Spotlight commentary— Unraveling #Tcell exhaustion: genetic screening meets in vitro modeling, by @AlfredZippelius, @MarcelTrefny, @priska_adm, and Schmid describing a recent @SciImmunology paper from the @EJohnWherry group.
https://t.co/rOG1wZgEYm

[LSSI Reddy @ReddyLab_ETHZ]

We’re excited to present our most recent preprint on bioRxiv “Multimodal single-cell profiling of T cell specificity and reactivity in lung cancer ” https://t.co/xmL6snv7hy

[Heinz Läubli @LImmunotherapy]

Great collaboration with Hutter lab. Philip Schmassmann identifies Sig9 as new target in GBM.
#glycotime

Targeting the Siglec–sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma | Science Translational Medicine https://t.co/0k78JB7A5l

[Priska Auf der Maur @priska_adm]

The Bassermann lab @TumTransla has several open #positions in #Munich

#postdoc
https://t.co/ciI4DMZ821
#PhD
https://t.co/XhGQjHtw08
and a technical assistant
https://t.co/uE0prj8Dva

Are you a science enthusiast, interested in cancer biology and protein turnover grab a seat🍻

[Jan Böttcher @JBoettcherLab]

We are excited that our latest study on cDC1-mediated coordination of anti-cancer responses by tumor-infiltrating TCF1+stem-like CD8+ T cells, led by @PhilippaMeiser is now published OPEN ACCESS in @Cancer_Cell! https://t.co/HRLzKv6QDs 🧵👇1/n

[Jan Böttcher @JBoettcherLab]

We are thrilled that our recent study lead by @BayerlFelix is out in @ImmunityCP today. We addressed the question how cDC1 dysfunction is regulated in tumors and to which extent this contributes to cancer immune evasion. It is Open Access!👇
https://t.co/Kjm87tegxm

A short 🧵:

[Jane Stinchcombe @StinchcombeJane]

Delighted to share our latest research following T cell receptor (TCR) by 3D TEM and showing ectocytosis makes TCR signalling self limiting at the immune synapse.

Many thanks to everyone involved.
@griffiths_lab https://t.co/5kNV1Sf9OW

[LMU Clinical Pharmacology @KlinPharm]

#Koboldlab news: Big congrats to Florian Märkl and @BenmebarekMr and everyone involved @SophiaStock_ @cadilhabl @philippjie @MarrCarsten @BergweltMichael 🍸🍸

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity https://t.co/L6YknZXZsv @NKirchhammer @KarenODixon @AlfredZippelius @MikaelPittet

[Ana Luisa Correia @alpcorreia]

👇We have a #Postdoc position funded by @EMBO @EMBO_YIP to study tissue-specific immune regulation of metastasis.
Come join us in #Lisbon @Neuro_CF @ChampalimaudF

👉Apply: https://t.co/J6xxCRvaer

[Marcel Trefny @MarcelTrefny]

@priska_adm @CellRepMed So great to see this paper online 🤩🥳

[Priska Auf der Maur @priska_adm]

Very excited to share our work on #resistance to PI3Kα inhibition in #BreastCancer published online today in @CellRepMed 🤩

#OpenAccess
📰 https://t.co/5FfCWoOUnf

Summary 🧵👇
1/10

[Nature Biotechnology @NatureBiotech]

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia https://t.co/5Mwx3GdGZP

[Ana Luisa Correia @alpcorreia]

Thrilled to share my Perspective on how #TissueImmunity selectively restrains the growth of metastases - an exciting avenue for developing #Immunotherapies for long-lasting control of #Metastasis
Thanks Lucy Bird and @NatRevImmunol for the opportunity!
👉https://t.co/zeHt9atpQ5

[Universität Basel @UniBasel]

Eine Forschungsgruppe der @UniBasel hat ein Gen identifiziert, welches T-Lymphozyten in die Erschöpfung treibt. Dies schafft neue Ansatzpunkte für wirksamere Immuntherapien.
@DepBiomedicine @snf_ch
https://t.co/PpW0bef7Us

[Nature Communications @NatureComms]

Targeting SNX9 to prevent CD8 T cell exhaustion and enhance anti-tumor immunity.
https://t.co/QWlDfSxUTW
@MarcelTrefny @AlfredZippelius @DepBiomedicine @NKirchhammer @priska_adm #CancerResearch @natrescancer